PhytoCeutica

Phytoceutica, Inc. develops traditional Chinese medicine into FDA-approved prescription drugs for the treatment of cancer. It focuses on

Phytoceutica, Inc. develops traditional Chinese medicine into FDA-approved prescription drugs for the treatment of cancer. It focuses on preclinical studies, clinical investigations, and a platform technology to assess botanical quality control and reproducibility. The company provides PHY906, a 4-herb traditional Chinese medicine reducing the toxic effects of chemotherapy, as well as potentiating chemotherapy's antitumor effect; and PHY626, a herbal extract that possesses contents of amino acids and isoflavones. It also offers PHY808, a preclinical development for the treatment of cancer, rheumatism, and other inflammatory syndromes; and PHY777, a herb, which serves as an immune modulator with anti-oxidative activity. In addition, the company provides PhytomicsQC, a technology platform developed and patented for the characterization of botanical drugs; and PhytomicsQC that measures and compares patterns of spectrum of phytochemicals and the interactions of phytochemicals on a living cell. Further, it offers PhytoViewerCA to analyze chemical fingerprint patterns, identify the compounds, define the signature pattern, calculate similarity coefficients, and assign quantitative pattern cut-offs of acceptance or rejection of manufactured batches; and PhytomicsQC, a platform to characterize phytochemical compound pattern. Further more, the company provides Phytomics Similarity Index Pattern Comparison, a method to compare information intensive patterns that considers individual peak intensities obtained from LC/MS analysis; and PhytoViewer, a proprietary software package, which combines tools for the analysis of LC/MS and genomics data. Phytoceutica, Inc. was founded in 1999 and is based in New Haven, Connecticut.